Industries We Serve with Our Market Access, Quality Compliance & Regulatory Affairs Consulting Services

Cisema provides trusted regulatory affairs consulting services to help companies succeed across the Asia Pacific region. With deep expertise in China and the Hong Kong SAR, and expanding support across Southeast Asia, South Korea and Taiwan, we work with clients in diverse regulatory environments. Backed by decades of experience in regulatory affairs consulting, our team of regulatory experts delivers comprehensive regulatory services, providing end-to-end support for compliance and approvals. We have a proven track record of achieving successful regulatory outcomes for medical devices, IVDs, pharmaceuticals, quasi-drugs, cosmetics, health products, consumer goods, and industrial products. Our expert guidance ensures smooth market entry, regulatory compliance, and long-term success in one of the world’s most dynamic regions.

Two men in business suits sitting at a table engaged in a meeting with a third person.
Regulatory submissions

Industries We Serve

We support companies in a wide range of regulated industries, with a focus on streamlining compliance and approvals for our clients. We help them meet the evolving regulatory landscape and compliance requirements, accelerate approvals, and maintain product quality throughout the lifecycle. For each industry, we develop a tailored regulatory strategy and identify the optimal regulatory pathway to ensure efficient progression through approval stages and reduce risks.

Medical Devices

We assist manufacturers with product registration, clinical trials, post-market surveillance, quality control, and the implementation of quality management systems. As well as inspection and sourcing services, in China, Hong Kong and Taiwan and across Southeast Asia.

Mehr erfahren

In Vitro Diagnostics (IVDs)

Our team helps IVD companies navigate rigorous clinical validation, registration, and post-market requirements, ensuring compliance with the latest regulatory and clinical guidelines. We also deliver quality control, inspection, and sourcing services across China, Hong Kong, Taiwan and Southeast Asia.

Mehr erfahren

Pharmaceuticals

From early development through to commercialization, we support drug manufacturers throughout the entire drug development process, providing strategic guidance, submission support, and GMP alignment for success across Asia Pacific.Our team has extensive expertise in the preparation and submission of drug applications, including ANDAs and NDAs, ensuring regulatory compliance and smooth interactions with agencies.

Mehr erfahren

Biotech

We provide regulatory guidance for biotech innovators across Asia Pacific, supporting clinical trial design, biosafety clearance, import licensing, and alignment with regulators' expectations.

Mehr erfahren

Quasi-Drug Products

We support foreign manufacturers throughout the entire Korean quasi-drug registration process, from initial feasibility assessment and classification through MFDS submission, Korean labeling, import coordination, and ongoing lifecycle compliance.

Mehr erfahren

Cosmetics & Ingredients

We support cosmetic and ingredient manufacturers throughout the full product lifecycle in China and Taiwan from pre-registration or notification to post-market. We are your “Responsible Person” and ensure quality compliance with Chinese and Taiwanese regulations, assisting in preparation for NMPA and TFDA audits as required.

Mehr erfahren

Health Foods & Supplements

We handle regulatory strategies, raw material approvals, testing, and registrations for dietary supplements and health foods. Our team ensures quality compliance and smooth market entry.

Mehr erfahren

Veterinary Drugs & Pet Food

We support MARA interactions, registration, licensing, and testing for pet foods and veterinary medicinal products entering the Chinese market.

Mehr erfahren

Industrial Goods & Consumer Products

We help you get your products on the market faster, from electronics and toys to machinery, telecom, and automotive parts. Our team manages CCC, HAF 604, CML, CEL, RoHS, NAL, SRRC, and more. From testing and documentation to renewals and authority approvals, we streamline every step to ensure full compliance with China’s regulations.

Mehr erfahren

Why Work with Cisema?

One Partner, Full Lifecycle Support

From pre-market strategy to post-market compliance, we provide support to internal regulatory teams and ensure seamless lifecycle management.

Regional Reach, Global Presence

Based in Asia and Europe with a global team delivering global reach.

Cross-Industry Expertise

Pharma, biotech, medical devices, cosmetics, supplements, veterinary, industrial and consumer goods.

Proven Results

Over 20 years of regulatory submissions, regulatory expertise, and approvals to drive business success.

Why Work with Cisema

Aktuelle Einblicke

Mehr anzeigen

Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

Updated MDACS guidance creates a new pathway for qualifying technologies and outlines the evidence required for priority consideration.

August 3, 2026
Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing
Zurück
Zurück

Get in Touch with Our Regulatory Affairs Experts

And discover how we can support you across your various projects in Asia Pacific.

Angebot anfordern